Lipomics to Develop Dxs for Metabolic Diseases in Alliance With UCD
GenomeWeb News
Feb 26, 2007
By a GenomeWeb staff reporter
Lipomics and the University of California, Davis will study metabolic diseases with “an emphasis on personalized medicine,” the company said today.
Lipomics uses bioinformatics and other analytical tools to develop profiles of lipid metabolites it can use to develop diagnostics for metabolic diseases.
Under the agreement, Lipomics will retain “certain rights to develop diagnostic applications based on the data from the studies,” the company said.
Financial terms of the agreement were not released. |
